Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2021-12-28 Governance Information
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
投资者关系管理档案制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management Archive System" and details the company's internal procedures for managing investor relations documentation and archives. It includes sections on the responsibilities of the board office, filing timelines, confidentiality, and retention periods. The document is a formal announcement of a governance-related policy approved by the board, with no financial data, no earnings or annual report content, and no shareholder voting results. It is not a report itself but a governance or management information disclosure. Given the content focuses on internal governance procedures related to investor relations, the most appropriate classification is Governance Information (CGR). The document length is short (1879 characters), and it is not an announcement of a report publication but a policy document. Therefore, the classification is CGR with high confidence.
2021-12-28 Chinese
监事会制度
Governance Information Classification · 95% confidence The document is titled as a supervisory board system (监事会制度) for Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the rules, composition, powers, meeting procedures, and responsibilities of the supervisory board. It includes no financial statements, no earnings data, no voting results, no executive changes, no legal proceedings, and no announcements of reports. It is a governance-related document describing internal rules and structure of the supervisory board. Therefore, it fits best under Governance Information (CGR). The document length is 3179 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2021-12-28 Chinese
董事会制度
Governance Information Classification · 100% confidence The document is titled as the "Board of Directors System" of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the rules, responsibilities, composition, meeting procedures, and duties of the board of directors and the board secretary. It includes sections on board meetings, voting, committees, and governance practices. There is no financial data, audit information, or report of financial results. The document is a governance framework document rather than a report or announcement of financial results or corporate actions. It is not a report publication announcement since it contains substantive content rather than a brief notice. The content fits the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2021-12-28 Chinese
关于拟修订公司章程公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding proposed amendments to the company's Articles of Association (公司章程). It includes specific references to legal and regulatory frameworks such as the Company Law, Beijing Stock Exchange listing rules, and other governance-related provisions. The content focuses on governance structure, shareholder rights, board responsibilities, and related corporate governance matters. There is no indication of financial statements, audit results, earnings data, or capital changes. The document is not a report itself but a formal announcement of proposed governance changes. Therefore, the filing type best fitting this document is Governance Information (CGR). The document length and detail confirm it is not a brief announcement or a simple notice but a substantive governance-related filing.
2021-12-28 Chinese
独立董事关于第三届董事会第八次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the independent directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding their prior approval opinions on matters discussed at the company's third board of directors' eighth meeting. It references compliance with company law, securities law, and stock exchange listing rules, and provides opinions on related party transactions to be submitted to the board. The document is short (779 characters) and serves as a formal announcement of board-related opinions rather than a full report or detailed financial disclosure. It does not contain financial statements, earnings data, or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2021-12-28 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司预计2022年日常性关联交易的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special verification opinion from a sponsoring securities company regarding the expected 2022 routine related-party transactions of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes transaction details, pricing policies, fairness opinions, internal board resolutions, and independent director opinions. The document is not a full annual or interim financial report, nor is it an announcement of voting results or a proxy statement. It is a specialized audit or verification report related to regulatory compliance and internal controls on related-party transactions, which fits the definition of an Audit Report / Information (AR). The document length is 4514 characters, which is sufficient for a substantive report rather than a brief announcement. Therefore, the classification is AR with high confidence.
2021-12-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.